Companies Harness Benefits of Bempedoic Acid to Gain FDA Approval for NDAs

Manufacturers in the cholesterol lowering drugs market are increasing research activities to include bempedoic acid for the development of new drugs. For instance, in May 2019, Esperion - a U.S. pharmaceutical company, announced the FDA approval for new drug applications (NDAs) involving the bempedoic acid.

Companies are harnessing the advantages of bempedoic acid to treat a host of health conditions such as hypercholesterolemia and to treat patients with high cardiovascular risks. As such, the hypercholesterolemia indication segment of the cholesterol lowering drugs market is projected to reach a value of ~US$ 19.6 Bn by 2027. Hence, healthcare providers in the market for cholesterol lowering drugs are recommending the intake of bempedoic acid with statins to lower complications of LDL (Low-density Lipoproteins) associated with hypercholesterolemia.

Growing awareness about bad cholesterol is one of the key drivers that is triggering the growth of the cholesterol lowering drugs market. Companies are referring investigational studies to understand which drugs are well-tolerated in patients and make improvements according to the results.

cholesterol lowering drugs market infographic

Request a sample to get extensive insights into the Cholesterol Lowering Drugs Market

Precision Medicines Encourage Decline of LDL-C Levels in Hyperchoesterolaemia Patients

In order to improve cardiovascular risk assessment, companies are increasingly adopting the ‘personalized’ approach to achieve better outcomes in patients. This trend has led to the concept of precision medicine in the market for cholesterol lowering drugs. The coronary artery disease indication segment of the cholesterol lowering drugs market is estimated to reach a value of ~US$ 14.9 Bn by 2027. Hence, manufacturers are increasing clinical trials that show promising outcomes of PCSK9 inhibitor monoclonal antibodies for the treatment of coronary artery diseases.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Companies in the cholesterol lowering drugs market are increasing their production capacities to manufacture Evolocumab used by high-risk patients. They are also tapping into opportunities to manufacture Canakinumbab, an effective antibody that leads to significant decline in cardiovascular events. Manufacturers are developing improved PCSK9 inhibitors to treat hyperchoesterolaemia. They are focusing on secondary prevention statins to lower LDL-C in patients. Improved outcomes associated with CPSK9 inhibitors are translating into revenue sources for companies in the market for cholesterol lowering drugs.

Strategic Licensing Agreements Help Manufacturers Market Cholesterol Lowering Drugs in Europe

Various clinical trials have concluded that bile acid biosynthesis helps in reverse cholesterol transport (RCT). In a research published in MDPI, an open access publishing platform for scholarly research studies, reveals that RCT helps in reducing cholesterol via its conversion into bile acids in patients. On the other hand, companies are entering into licensing agreements to bolster their credibility credentials in the global cholesterol lowering drugs market. For instance, in January 2019, global pharmaceutical company Daiichi Sankyo Europe announced its European licensing agreement with Esperion, to market bempedoic acid and Ezetimibe combination tablet for cholesterol patients.

Strategic agreements are helping manufacturers to expand their cardiovascular portfolio, since cholesterol increases risks of coronary heart diseases. Companies are eyeing business expansions in the U.K. and Switzerland. Patients are increasingly benefitting from the advantages of bempedoic-induced drugs, as novel drug help to reduce fatty acid synthesis in liver.

Bempedoic-induced Drugs Reduce Incidence of Side Effects of Statins

Statins & combination drug class segment of the cholesterol lowering drugs market is expected to reach a value of ~US$ 19.8 Bn by 2021. However, side effects associated with statins, such as muscle pain and undesired reactions with other medicines, act as a barrier for its adoption by patients. Hence, manufacturers are introducing new class of oral cholesterol lowering drugs that are well tolerated in patients.

Improved drug formulations in new oral drugs are being used as an alternative to statins. Manufacturers in the cholesterol lowering drugs market are increasing production capabilities to include bempedoic acid in new drug formulations. They are increasing efforts to obtain approvals for bempedoic-induced drugs in Europe.

Moreover, companies in the market for cholesterol lowering drugs are increasing research activities to develop drugs using bempedoic acid to reduce incidences of heart attack and stroke in patients. High prevalence of LDL cholesterol is another driver fueling the demand for cholesterol lowering drugs.

cholesterol lowering drugs market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on Cholesterol Lowering Drugs Market

Analysts’ Viewpoint

Top medical innovations in the cholesterol lowering drugs market primarily involve bempedoic acid in drug formulations. Apart from North America and Europe, manufacturers are leveraging opportunities in Asia Pacific, since governments of rapidly developing countries are increasingly investing toward the strengthening of their healthcare infrastructure.

Though statins are projected for widespread adoption in the coming years, its side effects are a major concern for healthcare companies. Hence, companies in the cholesterol lowering drugs market should increase awareness about the intake of statins with Ezetimibe or PCSK9 inhibitors to reduce LDL-C and boost drug tolerance in patients. They should increase production of PCSK9 inhibitors, since these drugs are anticipated to witness high adoption during the forecast period.

Cholesterol Lowering Drugs: Overview

  • High cholesterol level increases the risk of heart diseases and heart attacks. Medications can help improve and maintain proper cholesterol levels in the human body.
  • Cholesterol lowering medication includes statins, PCSK9 inhibitors, and cholesterol absorption inhibitors
  • Statins are widely used cholesterol drugs and play an important role in treating elevated cholesterol level and atherosclerosis.
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new medication that decreases the low density lipoprotein cholesterol. It is approved for the treatment of atherosclerotic cardiovascular disease in patients who require reduction of LCL-C.

Cholesterol Lowering Drugs Market: Key Drivers

  • Increase in prevalence of coronary artery disease due to the formation of bad cholesterol is a major factor responsible for the global market growth
  • Prevalence of atherosclerosis, which is one of the main causes of coronary artery disease, is expected to increase in the near future, due to the rise in bad cholesterol. This is expected to boost the market growth.
  • According to the CDC database, 2017, over 365,914 people died in the U.S. due to coronary artery disease. About 18.2 million adults aged 20 years and older have coronary artery disease (about 6.7%).
  • Moreover, development of drug formulation for cholesterol lowering, new therapies such as emergence of PCSK9 inhibitors, and growing awareness about cardiovascular diseases are some of the major factors responsible for the growth of the cholesterol lowering drugs market 

Cholesterol Lowering Drugs Market: Segmentation

  • Based on drug class, the cholesterol lowering drugs market has been segmented into statins and combination, PCSK9 inhibitors, bile acid sequestrants, fibrates, cholesterol absorption inhibitors, and others
  • In terms of indication, the cholesterol lowering drugs market has been divided into hypercholesterolemia, coronary artery disease, and higher triglycerides
  • In terms of distribution channel, the cholesterol lowering drugs market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights
  • The report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027 along with market size estimations. 

Cholesterol Lowering Drugs Market: Regional Overview

  • In terms of region, the global cholesterol lowering drugs market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
  • The current and future market sizes, in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which would help new companies willing to enter the market and the existing companies to increase their market shares, and help in their decision-making process 

Major Players in Cholesterol Lowering Drugs Market

  • The report concludes with the company profiles section that includes key information about major players in the market
  • Key players analyzed in this report include
    • Sanofi
    • Pfizer, Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Merck & Co., Inc.
    • Amgen Inc.
    • Takeda Pharmaceutical Company Limited
    • Sun Pharmaceutical Industries Ltd.
    • AbbVie, Inc.
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Cholesterol Lowering Drugs Market – Scope of the Report

TMR’S report on the global cholesterol lowering drugs market studies past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period from 2019 to 2027. The report provides the overall market revenue of the cholesterol lowering drugs market for the period of 2017–2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the cholesterol lowering drugs market for the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involves bulk of research efforts, wherein, analysts carry out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cholesterol lowering drugs market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approach to study various phenomena in the cholesterol lowering drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the cholesterol lowering drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the cholesterol lowering drugs market.

The report delves into the competitive landscape of the cholesterol lowering drugs market. Key players operating in the cholesterol lowering drugs market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the cholesterol lowering drugs market that have been profiled in this report.

Key Questions Answered in This Report on Cholesterol Lowering Drugs Market Report

  • What is the sales/revenue generated by each drug class segment of the cholesterol lowering drugs market across all regions during the forecast period?
  • What are the opportunities in the cholesterol lowering drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which region is likely to expand at the fastest CAGR during the forecast period?
  • Which cholesterol lowering drugs class, indication, and distribution channel segments are expected to generate maximum revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What was the market share or position of different companies operating in the global market in 2018?

Cholesterol Lowering Drugs Market – Research Objectives and Research Approach

The comprehensive report on the cholesterol lowering drugs market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, pipeline analysis, key brand sales analysis, key merger & acquisition, and disease prevalence rate of different diseases and conditions.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the cholesterol lowering drugs market, in terms of drug class, indication, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2027 has been provided herein. Such valuable insights enable market stakeholders in making informed business decisions for investment in the cholesterol lowering drugs market.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Cholesterol Lowering Drugs Market - Segmentation

TMR’s study on the cholesterol lowering drugs market includes information divided into four sections - by drug class, by indication, by distribution channel, and by region. Changing industry trends and other crucial market dynamics associated with these sections of the cholesterol lowering drugs market have been discussed in detail.

Drug Class

Statins & Combination

PCSK9 Inhibitors

Bile Acid Sequestrants

Fibrates

Cholesterol Absorption Inhibitors

Others

Indication

Hypercholesterolemia

Coronary Artery Disease

Higher Triglycerides

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Cholesterol Lowering Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, 2017–2027

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Key Drug Brand Analysis

    5.3. Key Merger & Acquisitions

    5.4. Pipeline Analysis 

    5.5. Global Prevalence of Cardiovascular Diseases

6. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2027

        6.3.1. Statins and Combination

        6.3.2. PCSK9 Inhibitors

        6.3.3. Bile Acid Sequestrants

        6.3.4. Fibrates

        6.3.5. Cholesterol Absorption Inhibitors

        6.3.6. Others

    6.4. Market Attractiveness, by Drug Class 

7. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Indication 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Indication, 2017–2027

        7.3.1. Hypercholesterolemia

        7.3.2. Coronary Artery Disease

        7.3.3. Higher Triglycerides

    7.4. Market Attractiveness, by Indication 

8. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Distribution Channel 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2027

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness, by Distribution Channel 

9. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness, by Region

10. North America Cholesterol Lowering Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2027

        10.2.1. Statins and Combination

        10.2.2. PCSK9 Inhibitors

        10.2.3. Bile Acid Sequestrants

        10.2.4. Fibrates

        10.2.5. Cholesterol Absorption Inhibitors

        10.2.6. Others

    10.3. Market Value Forecast, by Indication, 2017–2027

        10.3.1. Hypercholesterolemia

        10.3.2. Coronary Artery Disease

        10.3.3. Higher Triglycerides

    10.4. Market Value Forecast, by Distribution Channel, 2017–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Drug Class 

        10.6.2. By Indication 

        10.6.3. By Distribution Channel 

        10.6.4. By Country

11. Europe Cholesterol Lowering Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2027

        11.2.1. Statins and Combination

        11.2.2. PCSK9 Inhibitors

        11.2.3. Bile Acid Sequestrants

        11.2.4. Fibrates

        11.2.5. Cholesterol Absorption Inhibitors

        11.2.6. Others

    11.3. Market Value Forecast, by Indication, 2017–2027

        11.3.1. Hypercholesterolemia

        11.3.2. Coronary Artery Disease

        11.3.3. Higher Triglycerides

    11.4. Market Value Forecast, by Distribution Channel, 2017–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis 

        11.6.1. By Drug Class 

        11.6.2. By Indication 

        11.6.3. By Distribution Channel 

        11.6.4. By Country/Sub-region

12. Asia Pacific Cholesterol Lowering Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2027

        12.2.1. Statins and Combination

        12.2.2. PCSK9 Inhibitors

        12.2.3. Bile Acid Sequestrants

        12.2.4. Fibrates

        12.2.5. Cholesterol Absorption Inhibitors

        12.2.6. Others

    12.3. Market Value Forecast, by Indication, 2017–2027

        12.3.1. Hypercholesterolemia

        12.3.2. Coronary Artery Disease

        12.3.3. Higher Triglycerides

    12.4. Market Value Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis 

        12.6.1. By Drug Class 

        12.6.2. By Indication 

        12.6.3. By Distribution Channel 

        12.6.4. By Country/Sub-region

13. Latin America Cholesterol Lowering Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2027

        13.2.1. Statins and Combination

        13.2.2. PCSK9 Inhibitors

        13.2.3. Bile Acid Sequestrants

        13.2.4. Fibrates

        13.2.5. Cholesterol Absorption Inhibitors

        13.2.6. Others

    13.3. Market Value Forecast, by Indication, 2017–2027

        13.3.1. Hypercholesterolemia

        13.3.2. Coronary Artery Disease

        13.3.3. Higher Triglycerides

    13.4. Market Value Forecast, by Distribution Channel, 2017–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis 

        13.6.1. By Drug Class 

        13.6.2. By Indication 

        13.6.3. By Distribution Channel 

        13.6.4. By Country/Sub-region

14. Middle East & Africa Cholesterol Lowering Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2027

        14.2.1. Statins and Combination

        14.2.2. PCSK9 Inhibitors

        14.2.3. Bile Acid Sequestrants

        14.2.4. Fibrates

        14.2.5. Cholesterol Absorption Inhibitors

        14.2.6. Others

    14.3. Market Value Forecast, by Indication, 2017–2027

        14.3.1. Hypercholesterolemia

        14.3.2. Coronary Artery Disease

        14.3.3. Higher Triglycerides

    14.4. Market Value Forecast, by Distribution Channel, 2017–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis 

        14.6.1. By Drug Class 

        14.6.2. By Indication 

        14.6.3. By Distribution Channel 

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Share Analysis/Ranking, by Company (2018)

    15.3. Company Profiles

        15.3.1. Pfizer Inc.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Sanofi

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. GlaxoSmithKline plc

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Novartis AG

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Merck & Co., Inc. 

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Amgen, Inc.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Takeda Pharmaceutical Company Limited

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Sun Pharmaceutical Industries Ltd.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. AbbVie, Inc. 

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. Mylan N.V.

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Company Financials

            15.3.10.3. Growth Strategies

            15.3.10.4. SWOT Analysis

List of Tables

Table 01: Key Pipeline Analysis – Cholesterol Lowering Drugs Market

Table 02: Key Brand Sales Analysis – Cholesterol Lowering Drugs Market

Table 03: Key Mergers & Acquisition in the Cholesterol Lowering Drugs Market

Table 04: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027 

Table 05: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 06: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 07: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 08: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027 

Table 09: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027 

Table 10: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 11: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 12: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 13: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027 

Table 14: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 15: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 16: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 17: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027 

Table 18: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 19: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 20: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 21: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027 

Table 22: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 23: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 25: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027 

Table 26: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 27: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 02: Global Cholesterol Lowering Drugs Market Value (US$ Mn), by Drug Class, 2018

Figure 03: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Drug Class, 2018

Figure 04: Market Overview

Figure 05: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, 2017–2027

Figure 06: Global Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018

Figure 07: Global Cholesterol Lowering Drugs Market Value Share, by Indication, 2018

Figure 08: Global Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018

Figure 09: Global Cholesterol Lowering Drugs Market Value Share, by Region, 2018

Figure 10: Demographic Cardiovascular Death Statistics Globally-2017 (Millions)

Figure 11: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 12: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Statins & Combination, 2017-2027

Figure 13: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by PCSK9 Inhibitors, 2017-2027

Figure 14: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bile Acid Sequestrants, 2017-2027

Figure 15: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fibrates, 2017-2027

Figure 16: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cholesterol Absorption Inhibitors, 2017-2027

Figure 17: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

Figure 18: Global Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027

Figure 19: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Indication, 2018 and 2027

Figure 20: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Hypercholesterolemia, 2017–2027

Figure 21: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Coronary Artery Disease, 2017–2027

Figure 22: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Higher Triglycerides, 2017–2027

Figure 23: Global Cholesterol Lowering Drugs Market Attractiveness Analysis, by Indication, 2019–2027

Figure 24: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 25: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2017–2027

Figure 26: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027

Figure 27: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2017–2027

Figure 28: Global Cholesterol Lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 29: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Region, 2018 and 2027

Figure 30: Global Cholesterol Lowering Drugs Market Attractiveness Analysis, by Region, 2019–2027

Figure 31: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 32: North America Cholesterol Lowering Drugs Market Value Share, by Country, 2018 and 2027

Figure 33: North America Cholesterol Lowering Drugs Market Attractiveness, by Country, 2019–2027

Figure 34: North America Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 35: North America Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027 

Figure 36: North America Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027

Figure 37: North America Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027

Figure 38: North America Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027

Figure 39: North America Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 40: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 41: Europe Cholesterol Lowering Drugs Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 42: Europe Cholesterol Lowering Drugs Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 43: Europe Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 44: Europe Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027 

Figure 45: Europe Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027

Figure 46: Europe Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027

Figure 47: Europe Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027

Figure 48: Europe Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 49: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 50: Asia Pacific Cholesterol Lowering Drugs Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 51: Asia Pacific Cholesterol Lowering Drugs Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 52: Asia Pacific Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 53: Asia Pacific Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027 

Figure 54: Asia Pacific Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027

Figure 55: Asia Pacific Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027

Figure 56: Asia Pacific Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027

Figure 57: Asia Pacific Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 58: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 59: Latin America Cholesterol Lowering Drugs Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 60: Latin America Cholesterol Lowering Drugs Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 61: Latin America Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 62: Latin America Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027 

Figure 63: Latin America Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027

Figure 64: Latin America Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027

Figure 65: Latin America Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027

Figure 66: Latin America Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 67: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 68: Middle East & Africa Cholesterol Lowering Drugs Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 69: Middle East & Africa Cholesterol Lowering Drugs Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 70: Middle East & Africa Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 71: Middle East & Africa Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027 

Figure 72: Middle East & Africa Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027

Figure 73: Middle East & Africa Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027

Figure 74: Middle East & Africa Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027

Figure 75: Middle East & Africa Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027

Figure 76: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Cholesterol Lowering Drugs Market